Compugen (CGEN) Stock
Clinical stage biotech firm using computational drug discovery. Here's the price, business snapshot, and what's worth knowing about Compugen in October 2026.
Compugen Ltd (CGEN) is a clinical-stage biotechnology company that applies computational discovery to identify therapeutic targets, biomarkers and novel drug candidates, with a focus on immuno-oncology and precision medicine. The company leverages in‑house predictive platforms to nominate targets and advance a pipeline that can be progressed internally or licensed to partners. With a market capitalisation around $164.62M, Compugen is a small‑cap, development‑stage firm — potential upside from clinical or partnership milestones is matched by execution, funding and regulatory risks. Investors should note the firm may rely on collaborations, milestone payments or equity financing to fund development. Financial results and pipeline progress can be volatile; therapeutic development is lengthy and uncertain. This summary is for educational purposes only and is not personal investment advice. Investors should carry out their own research and consider risk tolerance before making investment decisions.
Compugen (CGEN) Stock Forecast
Analyst price target, next 12 months
$4.57
+97.9% vs today's $2.31
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Compugen have a consensus 12-month target of $4.57, above the current price of $2.31.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 22 Sep 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Compugen's stock, expecting it to rise significantly in value.
Financial Health
Compugen is performing well with strong revenue and profits, indicating solid financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Computational Discovery Edge
Compugen’s predictive platforms help nominate novel targets and biomarkers, a potential differentiator — though platform validation and clinical proof remain essential.
Milestones Drive Moves
Clinical readouts, partnerships or licensing deals can materially affect value; investors should expect volatility and monitor news flow closely.
Partnering Opportunities
The company’s model includes partnering to commercialise assets, which can accelerate development but depends on negotiation outcomes and counterparty execution.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
